What EndoStream Medical does

EndoStream Medical Ltd is an Israel-based, privately held medical device company that develops and commercializes the Nautilus Intrasaccular System, an intrasaccular flow diverter for the endovascular treatment of intracranial (brain) aneurysms. The device is built around a self-conforming scaffold that adapts to an individual aneurysm's shape and delivers maximal neck metal coverage, with key technical features including a thin delivery profile compatible with any 0.0165" microcatheter, complete radiopacity, an a-traumatic deployment, and a design without intraluminal components that eliminates the requirement for antiplatelet therapy. The Nautilus is engineered to promote intrasaccular thrombosis and endothelial remodeling, enabling progressive occlusion of wide-necked, ruptured, bifurcation, and complex cerebral aneurysms that are difficult to treat with standard coil embolization.

EndoStream generates revenue through direct hardware sales of the Nautilus Intrasaccular System, a Class III medical device sold to tertiary and quaternary care hospitals and neurovascular centers with interventional neuroradiology capabilities in European markets where the device holds CE mark. Pricing is negotiated individually with hospital procurement and is not publicly disclosed. In the United States, the device is currently limited by U.S. law to investigational use as EndoStream pursues FDA approval. The company's go-to-market relies on a typical enterprise medical device sales motion, complemented by clinical evidence generation through peer-reviewed publications (including a four-year follow-up first-in-human series and a 41-patient wide-necked aneurysm case series), presence at neurovascular and interventional radiology conferences, and a professional website targeting physician customers.

The company was founded by Danel Mayer (CEO) and Alon May (CTO), both experienced medtech entrepreneurs with prior exits and senior roles at Rapid Medical (MicroPort), Concentric Medical (Stryker), Kerberos (ev3), Superdimension (Covidien), EndoCross, and Intratech Medical. EndoStream employs between 11 and 50 people at its headquarters in Caesarea (Or Akiva area), Israel. Following its acquisition by Kaneka Corporation, EndoStream operates as a neurovascular-focused subsidiary within the larger Japanese healthcare conglomerate, with founders retaining leadership positions and operational autonomy, and with a strategic mandate to expand into the broader neurovascular device market alongside Kaneka's existing portfolio.

Name

EndoStream Medical

Legal name

EndoStream Medical Ltd

Website

https://endostream.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Israel-based EndoStream Medical develops and commercializes the Nautilus Intrasaccular System, a self-conforming intrasaccular flow diverter for treating brain aneurysms. The CE-marked device is sold directly to European hospitals and neurovascular centers while the company pursues US FDA approval.

Ownership category

akta.pro rank

Product category

Neurovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

akta.pro secondary industry

Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)

Keywords

• Intrasaccular flow diverter
• Brain aneurysm devices
• Neurovascular medical devices
• Endovascular aneurysm treatment
• Self-conforming scaffolds

Headquarters

HQ city

Or Akiva

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: EndoStream generates revenue through the sale of its Nautilus Intrasaccular System, a Class III medical device for neurovascular applications. The company operates as a medical device manufacturer selling to hospital cath labs and interventional neuroradiology departments. Revenue is derived from direct device sales to healthcare facilities in approved markets (Europe/CE mark regions).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

EndoStream Medical develops and manufactures the Nautilus Intrasaccular System, an a-traumatic, self-conforming intrasaccular flow diverter used to treat intracranial aneurysms. The device adapts to an aneurysm's unique shape, maximizes neck metal coverage, and enhances coil stability to promote intrasaccular thrombosis. It is CE marked and commercially sold in Europe, with US availability limited to investigational use.

Product overview

EndoStream Medical develops a single core product—the Nautilus Intrasaccular System (Nautilus™)—which is an intrasaccular flow diverter medical device for treating brain aneurysms. The device utilizes self-conforming scaffolds that adapt to an aneurysm's unique shape and provide maximal neck metal coverage. The Nautilus is CE marked and available for sale in Europe, but is not yet approved for sale or distribution in the United States.

Differentiator

Problem solved

Functional benefit

Brands

• Nautilus: Nautilus Intrasaccular System - A-traumatic, self-conforming intrasaccular flow diverter for aneurysm treatment, maximizing neck coverage and enhancing coil stability.

Products and services

• Nautilus Intrasaccular System An a-traumatic, self-conforming intrasaccular flow diverter designed for interventional neuroradiologists and neurosurgeons to treat wide-necked intracranial aneurysms, ruptured aneurysms, bifurcation aneurysms, and complex cerebral aneurysms. It maximizes neck coverage, enhances coil stability, eliminates the need for antiplatelet therapy by avoiding intraluminal components, and is fully radiopaque for procedural visibility. CE marked and sold to hospitals and neurovascular centers in Europe.

Quantifiable outcome

• Four-year follow-up data demonstrating complete aneurysm obliteration (Raymond Roy Class I) in first-in-human experience
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Stryker Neurovascular: Houses the Surpass flow diverter and the WEB intrasaccular device (via Terumo). A broad neurovascular incumbent that competes directly with EndoStream in flow diversion and intrasaccular treatment.
• Penumbra: Public neurovascular company with a portfolio spanning stroke thrombectomy and aneurysm embolization coils. Competes with EndoStream in the same interventional neuroradiology hospital accounts.
• MicroPort NeuroTech: Acquired Rapid Medical, founded by EndoStream's CEO, and markets the Tubridge flow diverter. Direct competitor in the intracranial flow-diversion market with a portfolio approach similar to other incumbents.
• Medtronic: Markets the Pipeline Embolization Device and Flow Re-Direction Endoluminal Device (FRED) for intracranial aneurysms. Dominant incumbent in the flow-diversion space and a key competitor to any intrasaccular entrant.
• Cerenovus (Johnson & Johnson MedTech): J&J's neurovascular business offering coils, flow diverters, and other devices for aneurysm treatment. Competes with EndoStream across the full neurovascular treatment workflow in tertiary care centers.

Direct peers

• Sequent Medical (acquired by Terumo, now Stryker): Developer of the WEB intrasaccular flow disruptor, the most direct intrasaccular competitor to the Nautilus. Acquired by Terumo and now part of Stryker's neurovascular portfolio, making it the closest technology and category peer.
• Cerus Endovascular: Developer of the Contour neurovascular embolization device, a competing intrasaccular device for bifurcation and wide-neck aneurysms. Targets the same interventional neuroradiology procedures as the Nautilus.

Emerging players

• Perflow Medical: Israel-based neurovascular company developing the Stream device for aneurysm treatment, with overlapping leadership (EndoStream's QA/RA director previously worked at Perflow). Comparable in stage, geography, and category focus.
• Phenox: Germany-based developer of flow diverters (p64, p48MW) and other neurovascular devices. A focused European competitor with overlapping technology in the flow-diversion category.
• Acandis: German neurovascular specialist with the Derivo and Acclino flow diverters and intrasaccular-type devices. Comparable in size and focus to EndoStream, targeting similar European tertiary accounts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/endostream-medica

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EndoStream Medical